Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Arista Networks

Global Payments

Arista Networks stock soared 26% last month as the demand for its cloud-networking technology surged. Eli Lilly's shares jumped 22% with diabetes drug Mounjaro fueling its revenue growth.

Should You Still Buy the S&P 500's Best-Performing August Stocks?

Novo Nordisk

Pfizer

Weight-loss drugs are taking the U.S. by storm. JPMorgan Chase (NYSE: JPM ) is forecasting that the market for weight-loss medications could reach $100 billion in annual sales.

Pound for Pound: 3 Buzzworthy Drug Stocks Worth Their Weight in Gold

Eli Lilly and Company (NYSE:LLY ) Morgan Stanley 21st Annual Global Healthcare Conference 2023 Call September 11, 2023 2:55 PM ET Company Participants Dan Skovronsky - Chief Scientific and Medical Officer Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn Okay. Great. I think we're going to get started.

Eli Lilly and Company (LLY) Morgan Stanley 21st Annual Global Healthcare Conference 2023 (Transcript)

Eli Lilly's stock is hitting new all-time highs as earnings continue to grow at a rapid rate. The company's breast cancer drug, Verzenio, and diabetes drug, Jardiance, have been delivering double-digit sales growth. The success of Lilly's newest drug, Mounjaro, which has seen sales growth of over 6,000% quarter over quarter, could drive future growth if approved for weight loss.

Eli Lilly Stock Hits New All-Time Highs: Is It Still A Buy?

Eli Lilly's type 2 diabetes treatment, called Mounjaro, is helping fuel new growth for the company. In addition to diabetes, Eli Lilly is looking to fast track Mounjaro for weight-loss approval by the FDA.

Investors May Not Have Seen the Best From Eli Lilly Stock Yet. Here's Why.

As Novo Nordisk and Eli Lilly duke it out in the weight-loss drug market with Ozempic, Wegovy and Mounjaro, drug company competitors plan to join the fray.

Big pharma's blockbuster obesity drug battle is just getting started, and it's headed for $100 billion

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

Eli Lilly is a healthcare giant poised to get even bigger. Regeneron Pharmaceuticals has nowhere to go but up.

3 Unstoppable Growth Stocks to Buy Right Now

Of the more than 40 current mega-cap stocks, only two have generated positive returns in each of the last five years. One is a highly diversified conglomerate, while the other is a fast-growing pharmaceutical company.

Only 2 Mega-Cap Monster Stocks Have Risen in Each of the Last 5 Years: Are They Buys Now?

The rise in obesity is having a massive impact on the global economy, according to Goldman Sachs. The bank estimates that obesity will drag down the world's GDP by $4 trillion in 2035.

The economic cost of obesity is expected to soar to $4 trillion by 2035. Weight loss drugs like Ozempic could change that, Goldman Sachs says.

Eli Lilly surged 15% in one day on enthusiasm for weight-loss and Alzheimer's drugs. But is LLY stock a buy now?

Is Eli Lilly Stock A Buy Now That It Has Hit A Profit-Taking Zone?

Accenture Plc

Eli Lilly and Accenture are at new highs after earnings. Both stocks are supported by strong technical ratings and are in buy zones.

Drug And Tech Services Stocks Surge To New Highs, Buy Zones With Strong Technical Ratings

Alphabet

NVIDIA

Tesla

If you're wondering which S&P 500 stocks the best mutual funds are buying — you might be surprised how selective the list is.

'Smart Money' Investors Pour $2 Billion Into Just 5 Stocks

Eli Lilly's drug Mounjaro has won the backing of Britain's drug cost-effectiveness watchdog as a diabetes treatment, Bloomberg News reported on Thursday.

Lilly's diabetes drug gains backing of UK watchdog -Bloomberg News

Lilly (LLY) reported earnings 30 days ago. What's next for the stock?

Why Is Lilly (LLY) Up 6.4% Since Last Earnings Report?

Eli Lilly and Denmark's Novo Nordisk are expected to roughly split the market for weight-loss drugs, both as diabetes and obesity treatments.

Weight-Loss Drug Market Can Hit $100 Billion, J.P. Morgan Says.

McDonald's

American Eagle Outfitters

DraftKings

DocuSign

e.l.f. Beauty

General Mills

Johnson & Johnson

Micron Technology

Otis Worldwide

Schlumberger

Dell Technologies

Here are some of the tickers on my radar for Thursday, Sept. 7, taken directly from my reporter's notebook.

Here are the 13 stocks Jim Cramer is watching, including Eli Lilly, McDonald's

SoFi Technologies

Due to what could be an unsustainable rally for equities, you may be looking for Nasdaq stocks to sell now. We've had an incredible run this year, but there are some additional indiciations that our luck has come to an end.

3 Nasdaq Stocks to Sell in September Before They Crash & Burn

Eli Lilly is making big plays in three hot markets: Alzheimer's, pain, and obesity. It's already on the cusp of getting medicines approved in those spaces.

Competing in These 3 Markets Could Send Eli Lilly Stock Soaring

Unlike the current five stocks with $1 trillion market caps, AI isn't a major factor for this contender. Instead, its fortunes rely largely on treating diabetes, obesity, and Alzheimer's disease.

Here's 1 Stock That Could Join Apple and Amazon in the $1 Trillion Club That You Might Have Overlooked

The pharma company's Wegovy medication helps it overtake luxury goods maker LVMH, with a market value of around $420 billion.

Novo Nordisk Is Now Europe's Biggest Company, Driven by Weight-Loss Drug. How Eli Lilly Could Benefit.

AstraZeneca

Bristol-Myers

Merck

The Medicare Modernization Act that established the Part D program in 2003 prohibited the federal government from negotiating drug prices with manufacturers. The Inflation Reduction Act, signed into law by President Biden last year, allows Medicare to start negotiating the prices it will pay for some widely used drugs.

8 Pharma Stocks Affected by New Drug Price Negotiation Rules

Astellas Pharma Inc

Amgen

Horizon Pharma

Novartis

Major pharmaceutical companies including Johnson & Johnson NYSE: JNJ, Novartis AG NYSE: NVS, Bristol-Myers Squibb (NYSE: BMY), Merck & Co., Inc. NYSE: MRK, Eli Lilly & Co. NYSE: LLY and Amgen Inc. NASDAQ: AMGN were trading normally following news that their drugs would be subject to next year's Medicare price negotiations.

How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks?

The negotiations with participating drug companies are likely to happen in 2023 and 2024 with the negotiated prices, if any, going into effect in 2026.

Medicare's First Price Negotiation List Targets Expensive Drugs (Revised)

Arthur J. Gallagher & Co.

Intuit

UBS Group AG

Propelled by strong earnings and upbeat guidance, the shares of several leading companies are now at their highest level in a year. And while some investors might be weary of stocks trading at 52-week highs, assuming they are destined to fall, many of the securities involved are from best-of-breed companies and household names.

7 Stocks Sitting At 52-Week Highs Right Now

Dick's Sporting Goods

Bullishness in AI and weight-loss treatments have made Nvidia and Eli Lilly hot investments to own this year. Dick's Sporting Goods crashed in August after the company cut its guidance, but its gains over the past three years remain impressive.

News for Eli Lilly Stock (LLY)